In Ohls’s study, treatment with oral and IV EPO was effective in preventing the decrease of Hb and HCT to the level of anemia of prematurity (<7 mg/dl) so that neither groups had a Hb less than 7 g/dL in the 4th week after birth.[12]. The gene discussed is EPO; the disease is anemia (phenotype).